Search

En la actualidad, hay un incremento en el consumo de infusiones debido a sus propiedades benéficas, las cuales se atribuyen a la presencia de compuestos fenólicos. Por lo anterior, el objetivo de este estudio fue evaluar el contenido fenólico, la capacidad antioxidante y la actividad antiinflamatoria de infusiones comerciales de hierbabuena (Mentha piperita L.), limón (Cymbopogon citratos), manzanilla (Matricaria chamomilla L.), árnica (Heterotheca inuloides) y boldo (Peumus boldus Molina) obtenidas en un supermercado en 2009. El contenido de fenoles y la capacidad antioxidante se determinaron por técnicas espectrofotométricas. Adicionalmente, la identificación y cuantificación de compuestos fenólicos también se llevó a cabo por HPLC. La actividad antiinflamatoria se evaluó mediante la inhibición de la enzima ciclooxigenasa-2 (COX-2). La infusión de boldo presentó el mayor contenido de compuestos fenólicos y la mayor capacidad antioxidante medida por la técnicas ABT, seguida de las infusiones de hierbabuena por el método de FRAP. En las infusiones evaluadas se identificaron diez diferentes compuestos, encontrándose en mayor concentración los compuestos catequina, epigalocatequina galato, ácido rosmarínico y eriocitrina. En cuanto a la capacidad inhibitoria sobre COX-2, las muestras de manzanilla y limón presentaron los mayores porcentajes de inhibición, seguida de la infusión de boldo. En general, los resultados sugieren que las infusiones comerciales de boldo y hierbabuena muestran propiedades biológicas con beneficios potenciales a la salud., Actually there is an increase on infusion consumption due their beneficial properties, which are attributable to the presence of phenolic compounds. By this reason, the aim of this study was to assess phenolic content, antioxidant capacity and anti-inflammatory capacity of commercial infusions of peppermint (Mentha piperita L.), lemon grass (Cymbopogon citratos), chamomile (Matricaria chamomilla L.), arnica (Heterotheca inuloides) and boldo (Peumus boldus Molina) obtained in supermarket in 2009. Phenols content and antioxidant capacity were defined by spectrophotometry techniques. Also, identification and quantification of phenolic compound was made by HPLC. The anti-inflammatory activity was assessed by inhibition of ciclooxigenasa-2 (COX-2) enzyme. Boldo infusion had greatest content of phenolic compounds and greater antioxidant capacity measured by ABT techniques, followed by chamomile infusions by FRAP method. In assessed infusions ten different compounds were identified, finding in higher concentration the compounds catechin, epigallocatechin gallate, rosmarinic acid and eriocitrin. As for inhibitory capacity on COX-2, chamomile and lemon samples had higher percentages of inhibition, followed by boldo infusion. In general, results suggest that boldo and peppermint commercial infusions show biological properties with potential benefits for health

En la actualidad, hay un incremento en el consumo de infusiones debido a sus propiedades benéficas, las cuales se atribuyen a la presencia de compuestos fenólicos. Por lo anterior, el objetivo de este estudio fue evaluar el contenido fenólico, la capacidad antioxidante y la actividad antiinflamatoria de infusiones comerciales de hierbabuena (Mentha piperita L.), limón (Cymbopogon citratos), manzanilla (Matricaria chamomilla L.), árnica (Heterotheca inuloides) y boldo (Peumus boldus Molina) obtenidas en un supermercado en 2009. El contenido de fenoles y la capacidad antioxidante se determinaron por técnicas espectrofotométricas. Adicionalmente, la identificación y cuantificación de compuestos fenólicos también se llevó a cabo por HPLC. La actividad antiinflamatoria se evaluó mediante la inhibición de la enzima ciclooxigenasa-2 (COX-2). La infusión de boldo presentó el mayor contenido de compuestos fenólicos y la mayor capacidad antioxidante medida por la técnicas ABT, seguida de las infusiones de hierbabuena por el método de FRAP. En las infusiones evaluadas se identificaron diez diferentes compuestos, encontrándose en mayor concentración los compuestos catequina, epigalocatequina galato, ácido rosmarínico y eriocitrina. En cuanto a la capacidad inhibitoria sobre COX-2, las muestras de manzanilla y limón presentaron los mayores porcentajes de inhibición, seguida de la infusión de boldo. En general, los resultados sugieren que las infusiones comerciales de boldo y hierbabuena muestran propiedades biológicas con beneficios potenciales a la salud., Actually there is an increase on infusion consumption due their beneficial properties, which are attributable to the presence of phenolic compounds. By this reason, the aim of this study was to assess phenolic content, antioxidant capacity and anti-inflammatory capacity of commercial infusions of peppermint (Mentha piperita L.), lemon grass (Cymbopogon citratos), chamomile (Matricaria chamomilla L.), arnica (Heterotheca inuloides) and boldo (Peumus boldus Molina) obtained in supermarket in 2009. Phenols content and antioxidant capacity were defined by spectrophotometry techniques. Also, identification and quantification of phenolic compound was made by HPLC. The anti-inflammatory activity was assessed by inhibition of ciclooxigenasa-2 (COX-2) enzyme. Boldo infusion had greatest content of phenolic compounds and greater antioxidant capacity measured by ABT techniques, followed by chamomile infusions by FRAP method. In assessed infusions ten different compounds were identified, finding in higher concentration the compounds catechin, epigallocatechin gallate, rosmarinic acid and eriocitrin. As for inhibitory capacity on COX-2, chamomile and lemon samples had higher percentages of inhibition, followed by boldo infusion. In general, results suggest that boldo and peppermint commercial infusions show biological properties with potential benefits for health

The discovery of two isoforms of cyclooxygenase, Cox-1 constitutive and Cox-2 inducible, has prompted the development of new molecules with high Cox-2 selectivity. These new NSAIDs belong to the coxib class and have theoretically a better digestive tolerability than classical NSAID have. In Belgium, rofecoxib ((Vioxx) and celecoxib (Celebrex) are commercialized. Rofecoxib is indicated in the symptomatic treatment of osteoarthritis (12.5 to 25 mg/d) and celecoxib is indicated in osteoarthritis (200 mg/d) and in rheumatoid arthritis (200 to 400 mg/d). Several studies have demonstrated their efficacy, similarly to classical NSAID as diclofenac (Voltaren), naproxen (Naprosyne), ibuprofen (Brufen) and their superiority compared to placebo. Their safety profile for gastrointestinal events is proven in patients without ulcer history compared to classical NSAID. However, the concomitant use of aspirin decreases the benefit as demonstrated for celecoxib at 400 mg/d but not investigated for rofecoxib. The selective inhibition of Cox-2 with no effect on Cox-1 favors cardiovascular events in patients at risk. Other side effects are similar to classical NSAID. Thus Cox-2 inhibitors NSAID are interesting molecules for their sparing gastrointestinal activity. They must be used with caution in patients with ulcer history, in the elderly and in patients requiring aspirin for cardiovascular prophylaxis., English Abstract, Journal Article, Review, SCOPUS: re.j, info:eu-repo/semantics/published

The discovery of two isoforms of cyclooxygenase, Cox-1 constitutive and Cox-2 inducible, has prompted the development of new molecules with high Cox-2 selectivity. These new NSAIDs belong to the coxib class and have theoretically a better digestive tolerability than classical NSAID have. In Belgium, rofecoxib ((Vioxx) and celecoxib (Celebrex) are commercialized. Rofecoxib is indicated in the symptomatic treatment of osteoarthritis (12.5 to 25 mg/d) and celecoxib is indicated in osteoarthritis (200 mg/d) and in rheumatoid arthritis (200 to 400 mg/d). Several studies have demonstrated their efficacy, similarly to classical NSAID as diclofenac (Voltaren), naproxen (Naprosyne), ibuprofen (Brufen) and their superiority compared to placebo. Their safety profile for gastrointestinal events is proven in patients without ulcer history compared to classical NSAID. However, the concomitant use of aspirin decreases the benefit as demonstrated for celecoxib at 400 mg/d but not investigated for rofecoxib. The selective inhibition of Cox-2 with no effect on Cox-1 favors cardiovascular events in patients at risk. Other side effects are similar to classical NSAID. Thus Cox-2 inhibitors NSAID are interesting molecules for their sparing gastrointestinal activity. They must be used with caution in patients with ulcer history, in the elderly and in patients requiring aspirin for cardiovascular prophylaxis., English Abstract, Journal Article, Review, SCOPUS: re.j, info:eu-repo/semantics/published